Skip to main content
. 2008 May 21;82(16):7913–7922. doi: 10.1128/JVI.02414-07

FIG. 8.

FIG. 8.

Suppression of endogenous TAL1 reduces HTLV-1 promoter activity. (A) Jurkat cells were transfected with 3 μg of pHTLV-LTR and 2 μg of either pSUPER-HSP (an shRNA targeting HSPC021 as a control) or pSUPER-TAL1. At 24 h after transfection, the luciferase activity was measured. (B) Efficiency of the shRNA directed against TAL1. Cells were transfected with pSG5-FLAG-TAL and either pSUPER-HSP or pSUPER-TAL1. Protein extracts of these cells were analyzed by immunoblotting (IB) using antibodies to FLAG (top panel) or β-actin (bottom panel). (C) The experiment was performed as for panel A, except that pHTLV-LTR was cotransfected with either pCMV or pCMV-TAL1 instead of pSUPER derivatives. Error bars indicate standard deviations.